Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

RITUXIMAB vs RIVASTIGMINE: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

RITUXIMAB vs RIVASTIGMINE: Safety Overview

Metric RITUXIMAB RIVASTIGMINE
Total FAERS Reports 178,614 9,123
Deaths Reported 28,910 2,232
Death Rate 16.2% 24.5%
Hospitalizations 54,631 2,716
Average Patient Age 54.6 yrs 80.0 yrs
% Female Patients 64.3% 59.5%
FDA Approval Date N/A Apr 21, 2000
Manufacturer Genentech, Inc. Novartis Pharmaceuticals Corporation
Route INTRAVENOUS TRANSDERMAL
Marketing Status Prescription Discontinued